682 studies found for:    Erbitux
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 1 and 2 Study of PX-866 and Cetuximab
Conditions: Incurable Metastatic Colorectal Carcinoma;   Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab;   Drug: Cetuximab
2 Terminated An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Condition: Colorectal Neoplasm
Intervention: Drug: Cetuximab
3 Completed
Has Results
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
Condition: Cancer of Head and Neck
Interventions: Drug: Erbitux, Paclitaxel & Carboplatin;   Radiation: Radiation
4 Recruiting Regorafenib and Cetuximab in Patients With Advanced Malignancy
Condition: Advanced Cancers
Interventions: Drug: Regorafenib;   Drug: Cetuximab;   Behavioral: Questionnaire
5 Recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin
6 Recruiting Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
7 Active, not recruiting Erlotinib in Combination With Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Erlotinib;   Drug: Cetuximab
8 Completed
Has Results
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Cetuximab plus Platinum-based Doublet Chemotherapy;   Drug: Cetuximab 500 mg/m^2;   Drug: Cetuximab 250 mg/m^2
9 Terminated EMMA-1 (Erbitux for Multiple Myeloma)
Condition: Multiple Myeloma
Intervention: Drug: Cetuximab +/- Dexamethasone
10 Withdrawn Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
Condition: Advanced Cancers
Interventions: Device: SIR-Spheres;   Drug: Cetuximab;   Drug: Erlotinib;   Procedure: Break-Through Scan
11 Recruiting Reirradiation and Erbitux in the HNSCC
Condition: Head Neck Cancer Squamous Cell.
Intervention: Drug: Erbitux
12 Terminated Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Drug: Avastin;   Drug: Erbitux
13 Terminated Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
Condition: Head and Neck Squamous Cell Cancer
Interventions: Drug: platinum plus radiation;   Drug: cetuximab plus radiation therapy
14 Completed
Has Results
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: Cetuximab;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation therapy
15 Completed Sirolimus and Cetuximab in Advanced Malignancies
Condition: Advanced Cancer
Interventions: Drug: Sirolimus;   Drug: Cetuximab
16 Not yet recruiting Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Tongue Cancer
Interventions: Biological: cetuximab;   Drug: cisplatin;   Radiation: external beam radiation therapy;   Other: laboratory biomarker analysis
17 Completed Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
Condition: Head and Neck Cancer
Interventions: Biological: IMC-A12 (cixutumumab);   Biological: cetuximab (Erbitux ®)
18 Completed A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma
Interventions: Drug: Cetuximab;   Drug: Bevacizumab
19 Recruiting A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) Patients Who Are Resistant or Ineligible/Intolerant to Platinum-based Chemotherapy.;   Recurrent Head and Neck Squamous Cell Carcinoma;   Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Drug: BYL719+cetuximab;   Biological: cetuximab
20 Withdrawn Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Head and Neck Cancer
Interventions: Drug: Cetuximab;   Drug: OSI-906;   Other: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years